A Phase Ib/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)
A study for patients with advanced melanoma using study drug Talimogene Laherparepvec
Sponsor: Amgen Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ6504
U.S. Govt. ID: NCT02263508
Contact: Kristina Lora: 212-305-0566 / ETCReferral@columbia.edu
Additional Study Information: The purpose of this study is to find out more about the Amgen agent called talimogene laherparepvec in people with advanced melanoma when given in combination with another drug developed by Merck called pembrolizumab. Melanoma is a type of skin cancer. Advanced melanoma means the tumor is not removable by surgery or has spread to other parts of the body.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Have you been diagnosed with advanced melanoma? Yes No
Is your tumor removable by surgery? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Kristina Lora
ETCReferral@columbia.edu
212-305-0566
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE